Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early…

UniQure has posted fresh data linking its hemophilia B gene therapy to the near-cessation of spontaneous bleeding.

A Dallas jury commanded Johnson & Johnson to pay up $1 billion to plaintiffs claiming injury from from the company’s metal-on-metal hip implants. This…

Boston Scientific is plunking down $75 million in cash to acquire Neovasc’s tissue processing technology, which it will integrate into its structural heart…

Pfizer’s longtime official Maddaluna is retiring as EVP, Thomas Willemsen will lead GSK China, Taro taps Sun Pharma CFO as new CEO. Plus more hirings, firings…

Japanese Big Pharma Takeda and VC Lightstone have come together to launch Cerevance, a newco focused on neuroscience R&D for neurological and psychiatric…

After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical…

Amryt, which is chaired by Shire founder Harry Stratford, has secured €20 million to fund a pivotal trial of its lead candidate in epidermolysis bullosa.